



# The Brazilian Journal of INFECTIOUS DISEASES

[www.elsevier.com/locate/bjid](http://www.elsevier.com/locate/bjid)



## Original article

# Transmitted drug resistance in patients with acute/recent HIV infection in Brazil



Ana Cristina G. Ferreira<sup>a</sup>, Lara E. Coelho<sup>a</sup>, Eduarda Grinsztejn<sup>a</sup>, Carlos S. de Jesus<sup>b</sup>,  
Monick L. Guimarães<sup>b</sup>, Valdiléa G. Veloso<sup>a</sup>, Beatriz Grinsztejn<sup>a</sup>, Sandra W. Cardoso<sup>a,\*</sup>

<sup>a</sup> Instituto Nacional de Infectologia Evandro Chagas, Fundação Oswaldo Cruz, Rio de Janeiro, RJ, Brazil

<sup>b</sup> Instituto Oswaldo Cruz, Fundação Oswaldo Cruz, Rio de Janeiro, RJ, Brazil

## ARTICLE INFO

### Article history:

Received 10 October 2016

Accepted 28 March 2017

Available online 21 May 2017

### Keywords:

HIV

Infection

Transmission

Primary resistance

Antiretroviral therapy

## ABSTRACT

**Introduction:** The widespread use of antiretroviral therapy increased the transmission of antiretroviral resistant HIV strains. Antiretroviral therapy initiation during acute/recent HIV infection limits HIV reservoirs and improves immune response in HIV infected individuals. Transmitted drug resistance may jeopardize the early goals of early antiretroviral treatment among acute/recent HIV infected patients.

**Methods:** Patients with acute/recent HIV infection who underwent resistance test before antiretroviral treatment initiation were included in this analysis. HIV-1 sequences were obtained using an in house protease/reverse transcriptase genotyping assay. Transmitted drug resistance was identified according to the Stanford HIV Database for Transmitted Drug Resistance Mutations, based on WHO 2009 surveillance list, and HIV-1 subtyping according to Rega HIV-1 subtyping tool. Comparison between patients with and without transmitted drug resistance was made using Kruskal-Wallis and Chi-square tests.

**Results:** Forty-three patients were included, 13 with acute HIV infection and 30 with recent HIV infection. The overall transmitted drug resistance prevalence was 16.3% (95% confidence interval [CI]: 8.1–30.0%). The highest prevalence of resistance (11.6%, 95% CI: 8.1–24.5) was against non-nucleoside reverse transcriptase inhibitors, and K103N was the most frequently identified mutation.

**Conclusions:** The high prevalence of nonnucleoside reverse transcriptase inhibitors resistance indicates that efavirenz-based regimen without prior resistance testing is not ideal for acutely/recently HIV-infected individuals in our setting. In this context, the recent proposal of including integrase inhibitors as a first line regimen in Brazil could be an advantage for the treatment of newly HIV infected individuals. However, it also poses a new challenge, since integrase resistance test is not routinely performed for antiretroviral naive individuals. Further studies on transmitted drug resistance among acutely/recently HIV-infected are needed to inform the predictors of transmitted resistance and the antiretroviral therapy outcomes among these population.

© 2017 Sociedade Brasileira de Infectologia. Published by Elsevier Editora Ltda. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

\* Corresponding author.

E-mail address: [sandra.wagner@ini.fiocruz.br](mailto:sandra.wagner@ini.fiocruz.br) (S.W. Cardoso).

<http://dx.doi.org/10.1016/j.bjid.2017.03.013>

1413-8670/© 2017 Sociedade Brasileira de Infectologia. Published by Elsevier Editora Ltda. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

## Introduction

The widespread usage of antiretroviral therapy (ART) and the increased survival of individuals using it favor the transmission of resistant HIV strains. Transmitted drug resistance (TDR) may be higher among patients with acute infection than in patients with chronic HIV infection.<sup>1,2</sup> This may lead to a more rapid decline in CD4 cell counts prior to ART initiation and limit both the magnitude and duration of treatment response.<sup>3–7</sup> TDR testing during acute HIV infection (AHI) provides increased sensitivity for the detection of primary drug resistance even before the overgrowth of drug-sensitive viral quasi-species.<sup>8</sup>

Early ART initiation during acute and recent HIV infection have benefits in limiting HIV reservoirs and improving immune response<sup>9,10</sup> if a full active ART regimen is promptly initiated. TDR may affect the time for ART response (virologic clearance) and jeopardize the early treatment goals among acute/early HIV infected individuals.

Currently, TDR testing is not standardized in most resource-limited settings, including Brazil. However, TDR surveillance is needed to assess the emergence and spread of drug-resistant strains in order to inform HIV treatment guidelines.

The HIV epidemic in Brazil persists concentrated and unabated among men who have sex with men (MSM), with a high proportion of them remaining unaware of their HIV status.<sup>11</sup> Rio de Janeiro is one of the major epicenters of the HIV epidemic in Brazil, contributing with 79,078 AIDS cases from 2000 to July 2015, holding the second position in number of cases within the country.<sup>12</sup>

We hereby report the prevalence of TDR and drug mutations associated with resistance in a cohort of acutely/recently HIV-infected individuals in Rio de Janeiro, Brazil, majority of whom MSM, to assess the need for routine TDR surveillance in Brazil.

## Methods

The Instituto Nacional de Infectologia Evandro Chagas – Fiocruz (INI) is the largest provider of primary, specialty, and tertiary care for individuals living with HIV/AIDS in Rio de Janeiro, Brazil. A clinical cohort has been maintained since 1986 and cohort procedures have been described elsewhere.<sup>13</sup> Since August 2013, we have been enrolling individuals with acute and recent HIV infection and offering them immediate ART, with the goal of reducing inflammation and HIV reservoirs.

For this analysis, we included 46 patients who were diagnosed with acute/recent HIV infection, between August/2013 and March/2016. Inclusion criteria were age over 18 years, documented seroconversion within the previous six months and no prior ART. HIV drug resistance testing was performed using an in-house protease/reverse transcriptase genotyping assay developed by FIOCRUZ,<sup>14</sup> which is certified by the National Institute of Allergy and Infectious Diseases virology quality assessment (NIAID-VQA). Drug resistance mutations (DRMs) were identified through the Stanford HIV Database for Transmitted DRM (TDRM/CPR Tool) Code Version 6.0<sup>15</sup> on the 2009

World Health Organization surveillance of transmitted DRMs list.<sup>16</sup> HIV-1 subtyping was obtained by using REGA HIV-1 & 2 Automated Subtyping Tool (Version 2.0).<sup>17</sup> Acute HIV infection (AHI) was defined as a negative result for a third generation HIV rapid test followed by a reactive result for the HIV antigen/antibody combination assay, or a detectable HIV RNA testing on pooled and subsequently confirmed with an individual HIV RNA test. Recent HIV infection (RHI) was defined as a reactive HIV serology and a documented HIV negative serology within the prior six months or a reactive Western Blot lacking p31 (pol) reactivity. Between-groups comparisons were made using Kruskal–Wallis test and Chi-square tests for continuous and categorical variables, respectively.


## Results

Out of the 46 included patients, 43 had a satisfactory protease/reverse transcriptase HIV-1 genotyping obtained prior to ART initiation and, of them 13 (30.2%) were defined as AHI and 30 (69.8%) as RHI (Fig. 1). The median time between the genotypic resistance test and HIV diagnosis was seven days (interquartile range [IQR]: 2–21 days). All patients were male at birth (one transgender woman), 95% reported having sex with men (Table 1). Median age at HIV diagnosis was 28 years old (IQR: 26–33 years), median CD4 and HIV RNA were 593 cells/mm<sup>3</sup> (IQR: 418–689 cells/mm<sup>3</sup>) and 4.8 log (IQR: 4.0–5.6 log), respectively. The most frequent HIV subtype was B (60.5%), followed by subtypes C (23.3%) and F (7%). No significant differences in socio-demographic and clinical variables were observed between patients with and without DRM (Table 1).

The overall TDR prevalence was 16.3% (95% confidence interval [CI]: 8.1–30.0%), being 23.1% (95% CI: 8.2–50.3%) among those diagnosed with AHI and 13.3% (95% CI: 5.3–29.7%) among those with RHI. Overall, five patients presented non-nucleoside reverse transcriptase inhibitors (NNRTI) DRMs, yielding a prevalence 11.6% (95% CI: 5.1–24.5%), and K103N was the most frequently identified resistance mutation (three patients). The other NNRTI DRMs were K101E and G190A (one patient each). Two patients presented protease inhibitors (PI) DRMs (prevalence of 4.7%, 95% CI: 1.3–15.5%) (I47A, I85V), whereas only one presented nucleoside reverse transcriptase inhibitors (NRTI) DRMs (prevalence of 2.3%, 95% CI: 0.4–12.1%, all thymidine analog mutations [TAMs], including M41L, D67N, T215S/C, K219Q/E). No triple-class TDR was identified.

Of note, two individuals were exposed to pre-exposure prophylaxis (PrEP, oral daily tenofovir plus emtricitabine) before HIV diagnosis. One of them, defined as AHI, started PrEP 175 days before seroconversion and the genotypic test revealed only a PI DRM (I47A). The other patient, with RHI, had interrupted PrEP use 140 days before seroconversion (after almost one year on PrEP), and at baseline presented DRMs for both NRTI (TAMs: M41L, D67N, T215S/C, K219Q) and NNRTI (G190A). Neither of them presented emtricitabine or tenofovir DRM.

Seven patients used post-exposure prophylaxis (PEP) prior to HIV diagnosis and only one of them presented with a DRM (K103N), which was not related to the ARV used as PEP (PI



**Fig. 1 – Flowchart with study population selection.**

**Table 1 – Patient characteristics and prevalence of transmitted drug resistance according to the WHO SDRM 2009 list.**

	No TDR (n = 36, 84%)	Any TDR (n = 7, 16%)	Total (n = 43)	p-value
Male sex at birth (%)	36 (100)	7 (100)	43 (100)	1
HIV risk exposure (%)				1
MSM	34 (94.4)	7 (100)	41 (95.3)	
TGW	1 (2.8)	0 (0)	1 (2.3)	
Heterosexual	1 (2.8)	0 (0)	1 (2.3)	
Age, median (IQR)	28.3 (25.8,33.2)	26.4 (26,31.2)	27.9 (25.8,33.4)	0.657
CD4, median (IQR)	588 (412, 721)	654 (453, 676)	593 (418, 689)	0.882
VL log, median (IQR)	4.9 (4.1, 5.5)	4.1 (3.8, 5.6)	4.8 (4.0, 5.6)	0.645
HIV subtype (%)				0.456
B	23 (63.9)	3 (42.9)	26 (60.5)	
C	7 (19.4)	3 (42.9)	10 (23.3)	
F	2 (5.6)	1 (14.3)	3 (7)	
B/F	1 (2.8)	0 (0)	1 (2.3)	
Other/unknown	3 (8.3)	0 (0)	3 (7)	
Stage of HIV infection (%)				0.655
Acute	10 (27.8)	3 (42.9)	13 (30.2)	
Recent	26 (72.2)	4 (57.1)	30 (69.8)	
PReP uptake (%)	0 (0)	2 (28.6)	2 (4.7)	0.023
PEP uptake (%)	6 (16.7)	1 (14.3)	7 (16.3)	1

TDR, transmitted drug resistance; MSM, men who have sex with men; TGW, transgender women; VL, HIV RNA viral load; PReP, pre-exposure prophylaxis; PEP, post-exposure prophylaxis.

based regimen). Two patients were on PEP at the moment of AHI diagnosis, both diagnosed with detectable HIV viral load and negative HIV rapid test and with no DRM at baseline. One of them had been using tenofovir, lamivudine and zidovudine (as PEP regimen) for four days prior to HIV diagnosis, with a subsequent switch to tenofovir, lamivudine and efavirenz. The second patient had been using zidovudine, lamivudine and lopinavir/ritonavir for eight days prior to HIV

diagnosis and, switching thereafter to tenofovir, lamivudine, lopinavir/ritonavir, and raltegravir.

## Discussion

Herein, we observed a TDR prevalence rate of 16.3% among acutely/recently HIV-infected individuals, in Rio de Janeiro, Brazil. This prevalence is within the range observed among

AHI/RHI in other settings in samples collected between 1995 to 2013 (8.3–21%),<sup>1,8,18–24</sup> with similar rates detected in Brazilian studies with samples collected between 1996 and 2012 (8.0–32%).<sup>25</sup> This rate was higher than those found in chronically HIV-infected individuals in Brazil, which varied from 3.6% to 11%.<sup>26,27</sup> Most studies addressing TDR enroll chronically HIV-infected participants<sup>28</sup> (after the overgrowth of more fit, drug-sensitive viral quasi-species) which limits the sensitivity of TDR detection.

The prevalence of NNRTI DRM found in the present study (11.6%) is higher than that observed among acute HIV infected individuals in Thailand (5.0%)<sup>19</sup> and in acute/recent HIV infected individual from China (1.7%).<sup>20</sup> Of note, NNRTI DRM prevalence was even higher than the rate previously reported by our group (6.3%)<sup>29</sup> in HIV recently infected individuals from Rio de Janeiro between 2005 and 2007 (classified using BED capture enzyme immunoassay).

The duration of ART availability has been an important predictor of TDR emergence.<sup>30</sup> Universal access to ART as well as treatment monitoring is available in Brazil since 1997. Brazilian treatment guidelines recommend NNRTI based regimens as first line ART since 2000, earlier than the ART scale up in other low/middle-income countries,<sup>19,20</sup> and this may have negatively impacted the emergence of NNRTI TDR in our setting.

Brazil has a concentrated epidemic among MSM, transgender women, female sex workers, and drug users.<sup>31</sup> While HIV prevalence among the general population is 0.6%, in MSM it reaches 14.2%.<sup>11</sup> Young MSM currently account for nearly 40% of the AIDS cases in the country, with increases of 41.3% (aged 15–19 years) and 25.1% (aged 20–24 years) observed from 2004 to 2013.<sup>12</sup> Targeting high-risk populations, early ART initiation and implementing TDR surveillance are utmost important strategies to control HIV epidemic.

In addition, acutely infected individuals account for 25–50% of the HIV transmission.<sup>32,33</sup> Transmission rates are sharply elevated during the first three months of HIV infection,<sup>34</sup> likely due to increased viral concentrations<sup>35</sup> and founder virus transmission advantages that facilitate transmission at a lower inoculum.<sup>36</sup> Phylogenetic analyses among MSM suggest large early-stage contributions,<sup>37,38</sup> posing a high risk of TDR spread through unprotected anal intercourse, as observed among young Thai MSM.<sup>19</sup>

Although highly effective, NNRTI regimens have low genetic barrier. Considering the high prevalence of NNRTI TDR observed in our patient sample, the use of efavirenz-based regimens without prior resistance testing might result in high rates of early virologic failure. Prompt initiation of fully active ART during acute/recent HIV infection can limit HIV reservoir seeding/size, improve immune response,<sup>2</sup> and reduce HIV transmission.<sup>39</sup> TDR may hamper virologic clearance; thus, jeopardize early treatment benefits in those individuals. Pre-treatment genotyping is of utmost importance to reach the goals of early treatment among acute/recent HIV infected individuals. Besides, pre-treatment genotyping (regardless of HIV infection stage) has been shown to be cost-effective in the Brazilian context.<sup>40</sup> Nevertheless, so far, it is solely recommended for pregnant women, vertically infected newborns, and individuals who were infected by a known HIV-infected partner under ART.<sup>41</sup>

Concerns have been raised regarding the increased risk of TDR<sup>42</sup> with the expansion of PrEP and PEP<sup>43</sup> uptake among high-risk populations. Of note, in our cohort PrEP and PEP users did not present any drug resistance mutation related to their regimen, which is in agreement with recent evidence from iPrEx.<sup>44</sup> Given the small number of individuals exposed to PrEP/PEP prior to seroconversion in our study, these results should be taken cautiously. Continuous surveillance will be needed to monitor resistance with the expansion of these strategies.

There are several limitations that need to be highlighted in the present study, some of which were already addressed throughout this discussion. First, the comparison of DRM prevalence by drug classes (i.e. NNRTI vs. PI) in our setting with those reported in the United States and other high-income settings must be done cautiously since the differences in first line ART regimen can influence this prevalence. Second, our study used a convenience sample from a single cohort in Rio de Janeiro; hence our results may not reflect the reality of other HIV populations in Brazil. And finally, our TDR prevalence may be underestimated considering that our resistance tests results were based on standard genotypic testing using Sanger sequencing that is the methodology we have been using for the routine care as well as in other research studies. Future studies implementing assays such as ultra-deep sequencing and allele-specific PCR are in need in order to evaluate TDR rates using tests that are more sensitive.

In conclusion, TDR surveillance among acutely/recently HIV-infected individuals can provide critical data to guide antiretroviral regimen choice. Notwithstanding our small and non-probabilistic sample, the results indicate that a NNRTI based regimen without prior resistance testing is not ideal for acutely/recently HIV-infected individuals in our setting. PI or integrase inhibitors (INSTIs) based regimens may be safer in order to avert onward TDR while preserving the benefits of early effective ART. In this context, the recent proposal of including an integrase inhibitor as first line ART regimen in Brazil could be an advantage for treating newly HIV infected individuals. However, it also poses a new challenge, since the integrase sequencing for resistance test is not routinely performed for ART naive individuals. Future research addressing TDR on acutely/recently HIV-infected are needed to provide information on predictors of TDR and ART outcomes in this population.

---

## Conflicts of interest

The authors declare no conflicts of interest.

---

## Acknowledgements

Beatriz Grinsztejn acknowledges the funding from the National Council of Technological and Scientific Development (CNPq) and the Research Funding Agency of the State of Rio de Janeiro (FAPERJ).

---

## REFERENCES

1. Hurt CB, McCoy SI, Kuruc J, et al. Transmitted antiretroviral drug resistance among acute and recent HIV infections in



- North Carolina from 1998 to 2007. *Antivir Ther*. 2009;14:673–8.
2. Jain V, Liegler T, Vittinghoff E, et al. Transmitted drug resistance in persons with acute/early HIV-1 in San Francisco, 2002–2009. *PLoS ONE*. 2010;5:e15510.
  3. Little SJ, Holte S, Routy J-P, et al. Antiretroviral-drug resistance among patients recently infected with HIV. *N Engl J Med*. 2002;347:385–94.
  4. Pillay D, Bhaskaran K, Jurriaans S, et al. The impact of transmitted drug resistance on the natural history of HIV infection and response to first-line therapy. *AIDS Lond Engl*. 2006;20:21–8.
  5. Taniguchi T, Nurutdinova D, Grubb JR, et al. Transmitted drug-resistant HIV type 1 remains prevalent and impacts virologic outcomes despite genotype-guided antiretroviral therapy. *AIDS Res Hum Retrovir*. 2012;28:259–64.
  6. Wittkop L, Günthard HF, de Wolf F, et al. Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a European multicohort study. *Lancet Infect Dis*. 2011;11:363–71.
  7. Phanuphak P, Sirivichayakul S, Jiamsakul A, et al. Transmitted drug resistance and antiretroviral treatment outcomes in non-subtype B HIV-1-infected patients in South East Asia. *J Acquir Immune Defic Syndr*. 2014;66:74–9.
  8. Jain V, Sucupira MC, Bacchetti P, et al. Differential persistence of transmitted HIV-1 drug resistance mutation classes. *J Infect Dis*. 2011;203:1174–81.
  9. Okulicz JF, Le TD, Agan BK, et al. Influence of the timing of antiretroviral therapy on the potential for normalization of immune status in human immunodeficiency virus 1-infected individuals. *JAMA Intern Med*. 2015;175:88–99.
  10. Laanani M, Ghosn J, Essat A, et al. Impact of the timing of initiation of antiretroviral therapy during primary HIV-1 infection on the decay of cell-associated HIV-DNA. *Clin Infect Dis Off Publ Infect Dis Soc Am*. 2015;60:1715–21.
  11. Kerr LRFS, Mota RS, Kendall C, et al. HIV among MSM in a large middle-income country. *AIDS Lond Engl*. 2013;27:427–35.
  12. Boletim Epidemiológico HIV/Aids. Departamento de DST, Aids e Hepatites Virais; 2015. Available from: <http://www.aids.gov.br/publicacao/2015/boletim-epidemiologico-aids-e-dst-2015> [accessed 05.06.16].
  13. Grinsztejn B, Veloso VG, Friedman RK, et al. Early mortality and cause of deaths in patients using HAART in Brazil and the United States. *AIDS Lond Engl*. 2009;23:2107–14.
  14. Delatorre E, Silva-de-Jesus C, Couto-Fernandez JC, Pilotto JH, Morgado MG. High HIV-1 diversity and prevalence of transmitted drug resistance among antiretroviral-naïve HIV-infected pregnant women from Rio de Janeiro, Brazil. *AIDS Res Hum Retrovir*. 2016, <http://dx.doi.org/10.1089/AID.2016.0159>.
  15. Gifford RJ, Liu TF, Rhee S-Y, et al. The calibrated population resistance tool: standardized genotypic estimation of transmitted HIV-1 drug resistance. *Bioinform Oxf Engl*. 2009;25:1197–8.
  16. Bennett DE, Camacho RJ, Otelea D, et al. Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update. *PLoS ONE*. 2009;4:e4724.
  17. Alcantara LCJ, Cassol S, Libin P, et al. A standardized framework for accurate, high-throughput genotyping of recombinant and non-recombinant viral sequences. *Nucleic Acids Res*. 2009;37:W634–42.
  18. Panichsillapakit T, Smith DM, Wertheim JO, Richman DD, Little SJ, Mehta SR. Prevalence of transmitted HIV drug resistance among recently infected persons in San Diego, CA 1996–2013. *J Acquir Immune Defic Syndr*. 2016;71:228–36.
  19. Ananworanich J, Sirivichayakul S, Pinyakorn S, et al. High prevalence of transmitted drug resistance in acute HIV-infected Thai men who have sex with men. *J Acquir Immune Defic Syndr*. 2015;68:481–5.
  20. Dai L, Li N, Wei F, et al. Transmitted antiretroviral drug resistance in the men who have sex with men HIV patient cohort, Beijing, China, 2008–2011. *Viral Immunol*. 2014;27:392–7.
  21. Ambrosioni J, Sued O, Nicolas D, et al. Trends in transmission of drug resistance and prevalence of non-B subtypes in patients with acute or recent HIV-1 infection in Barcelona in the Last 16 Years (1997–2012). *PLOS ONE*. 2015;10:e0125837.
  22. Truong H-HM, Kellogg TA, McFarland W, et al. Sentinel surveillance of HIV-1 transmitted drug resistance, acute infection and recent infection. *PLoS ONE*. 2011;6:e25281.
  23. Castor D, Low A, Evering T, et al. Transmitted drug resistance and phylogenetic relationships among acute and early HIV-1-infected individuals in New York City. *J Acquir Immune Defic Syndr*. 2012;61:1–8.
  24. Pineda-Peña A-C, Schrooten Y, Vinken L, et al. Trends and predictors of transmitted drug resistance (TDR) and clusters with TDR in a local Belgian HIV-1 epidemic. *PLoS ONE*. 2014;9:e101738.
  25. Avila-Rios S, Sued O, Rhee S-Y, Shafer RW, Reyes-Teran G, Ravasi G. Surveillance of HIV transmitted drug resistance in Latin America and the Caribbean: a systematic review and meta-analysis. *PLoS ONE*. 2016;11:e0158560.
  26. Gräf T, Passaes CPB, Ferreira LGE, et al. HIV-1 genetic diversity and drug resistance among treatment naïve patients from Southern Brazil: an association of HIV-1 subtypes with exposure categories. *J Clin Virol*. 2011;51:186–91.
  27. Medeiros LB, Lacerda HR, Cavalcanti AMS, de Albuquerque M, de FPM. Primary resistance of human immunodeficiency virus type 1 in a reference center in Recife, Pernambuco, Brazil. *Mem Inst Oswaldo Cruz*. 2006;101:845–9.
  28. Myers JE, Taylor BS, Rojas Fermín RA, et al. Transmitted drug resistance among antiretroviral-naïve patients with established HIV type 1 infection in Santo Domingo, Dominican Republic and review of the Latin American and Caribbean literature. *AIDS Res Hum Retrovir*. 2012;28:667–74.
  29. Velasco-de-Castro CA, Grinsztejn B, Veloso VG, et al. HIV-1 diversity and drug resistance mutations among people seeking HIV diagnosis in voluntary counseling and testing sites in Rio de Janeiro, Brazil. *PLoS ONE*. 2014;9:e87622.
  30. Frentz D, Boucher CAB, van de Vijver DAMC. Temporal changes in the epidemiology of transmission of drug-resistant HIV-1 across the world. *AIDS Rev*. 2012;14:17–27.
  31. De Boni R, Veloso VG, Grinsztejn B. Epidemiology of HIV in Latin America and the Caribbean. *Curr Opin HIV AIDS*. 2014;9:192–8.
  32. Brenner BG, Roger M, Routy J-P, et al. High rates of forward transmission events after acute/early HIV-1 infection. *J Infect Dis*. 2007;195:951–9.
  33. Lewis F, Hughes GJ, Rambaut A, Pozniak A, Leigh Brown AJ. Episodic sexual transmission of HIV revealed by molecular phylodynamics. *PLoS Med*. 2008;5:e50.
  34. Hollingsworth TD, Anderson RM, Fraser C. HIV-1 transmission, by stage of infection. *J Infect Dis*. 2008;198:687–93.
  35. Pilcher CD, Joaki G, Hoffman IF, et al. Amplified transmission of HIV-1: comparison of HIV-1 concentrations in semen and blood during acute and chronic infection. *AIDS Lond Engl*. 2007;21:1723–30.
  36. Carlson JM, Schaefer M, Monaco DC, et al. HIV transmission. Selection bias at the heterosexual HIV-1 transmission bottleneck. *Science*. 2014;345:1254031.

37. Brenner B, Wainberg MA, Roger M. Phylogenetic inferences on HIV-1 transmission: implications for the design of prevention and treatment interventions. *AIDS Lond Engl*. 2013;27:1045–57.
38. Volz EM, Ionides E, Romero-Severson EO, Brandt M-G, Mokotoff E, Koopman JS. HIV-1 transmission during early infection in men who have sex with men: a phylodynamic analysis. *PLoS Med*. 2013;10:e1001568, discussion e1001568.
39. Cohen MS, Dye C, Fraser C, Miller WC, Powers KA, Williams BG. HIV treatment as prevention: debate and commentary—will early infection compromise treatment-as-prevention strategies? *PLOS Med*. 2012;9:e1001232.
40. Luz PM, Morris BL, Grinsztejn B, et al. Cost-effectiveness of genotype testing for primary resistance in Brazil. *J Acquir Immune Defic Syndr*. 2015;68:152–61.
41. Protocolo Clínico e Diretrizes Terapêuticas para Manejo da Infecção pelo HIV em Adultos | Departamento de DST, Aids e Hepatites Virais. Available at: <http://www.aids.gov.br/publicacao/2013/protocolo-clinico-e-diretrizes-terapeuticas-para-manejo-da-infeccao-pelo-hiv-em-adul> [accessed 06.06.16].
42. Celum C, Hallett TB, Baeten JM. HIV-1 prevention with ART and PrEP: mathematical modeling insights into resistance, effectiveness, and public health impact. *J Infect Dis*. 2013;208:189–91.
43. Jain S, Oldenburg CE, Mimiaga MJ, Mayer KH. Longitudinal trends in HIV non-occupational post-exposure prophylaxis (NPEP) use at a Boston community health center between 1997 and 2013. *J Acquir Immune Defic Syndr*. 2015;68:97–101.
44. Liegler T, Abdel-Mohsen M, Bentley LG, et al. HIV-1 drug resistance in the iPrEx preexposure prophylaxis trial. *J Infect Dis*. 2014;210:1217–27.